- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01218009
A Twelve Month Long Term Safety Study to Evaluate the Safety of Albuterol in a Dry Powder Inhaler With Both Repeated and as Needed Dosing
A Multi-Center 52-Week Study to Assess the Safety of an Albuterol Dry-powder Inhaler in Subjects With Asthma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States
- Teva Clinical Study Site
-
-
California
-
Los Angeles, California, United States
- Teva Clinical Study Site
-
San Diego, California, United States
- Teva Clinical Study Site
-
-
Colorado
-
Centennial, Colorado, United States
- Teva Clinical Study Site
-
Denver, Colorado, United States
- Teva Clinical Study Site
-
-
Florida
-
Miami, Florida, United States
- Teva Clinical Study Site
-
-
Georgia
-
Gainesville, Georgia, United States
- Teva Clinical Study Site
-
-
Kentucky
-
Louisville, Kentucky, United States
- Teva Clinical Study Site
-
-
Maryland
-
Wheaton, Maryland, United States
- Teva Clinical Study Site
-
-
Minnesota
-
Minneapolis, Minnesota, United States
- Teva Clinical Study Site
-
Plymouth, Minnesota, United States
- Teva Clinical Study Site
-
-
Missouri
-
St. Louis, Missouri, United States
- Teva Clinical Study Site
-
-
Nebraska
-
Bellevue, Nebraska, United States
- Teva Clinical Study Site
-
Boys Town, Nebraska, United States
- Teva Clinical Study Site
-
-
New Jersey
-
Skillman, New Jersey, United States
- Teva Clinical Study Site
-
-
New York
-
Rochester, New York, United States
- Teva Clinical Study Site
-
Rockville Centre, New York, United States
- Teva Clinical Study Site
-
-
North Carolina
-
High Point, North Carolina, United States
- Teva Clinical Study Site
-
Raleigh, North Carolina, United States
- Teva Clinical Study Site
-
-
Ohio
-
Canton, Ohio, United States
- Teva Clinical Study Site
-
Cincinnati, Ohio, United States
- Teva Clinical Study Site
-
Sylvania, Ohio, United States
- Teva Clinical Study Site
-
-
Oregon
-
Eugene, Oregon, United States
- Teva Clinical Study Site
-
Portland, Oregon, United States
- Teva Clinical Study Site
-
-
Texas
-
El Paso, Texas, United States
- Teva Clinical Study Site
-
New Braunfels, Texas, United States
- Teva Clinical Study Site
-
San Antonio, Texas, United States
- Teva Clinical Study Site
-
-
Virginia
-
Burke, Virginia, United States
- Teva Clinical Study Site
-
-
Washington
-
Seattle, Washington, United States
- Teva Clinical Study Site
-
-
Wisconsin
-
Greenfield, Wisconsin, United States
- Teva Clinical Study Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Documented history of persistent asthma with rescue use of albuterol on average of at least once/ week over the 4-weeks prior to screening.
- Female subjects who are of childbearing potential (as judged by the investigator) must be currently using and willing to continue to use a medically reliable method of contraception for the entire study duration
- General good health
- Capable of understanding the requirements, risks, and benefits of study participation
- Non-smoker for at least one year prior to the screening visit and a maximum pack-year smoking history of 10 years
- Other criteria apply
Exclusion Criteria:
- Pregnancy, nursing, or plans to become pregnant or donate gametes (ova or sperm) for in vitro fertilization during the study period or for 30 days following the subject's last study related visit
- Participation in any investigational drug trial within 30 days preceding the screening visit
- A known hypersensitivity to albuterol or any of the excipients in the formulations.
- History of severe milk protein allergy
- History of a respiratory infection or disorder (including, but not limited to bronchitis, pneumonia, acute or chronic sinusitis, otitis media, influenza, etc) which is not resolved within 1 week prior to the Screening Visit.
- Use of any protocol prohibited concomitant medications for asthma or any protocol prohibited concomitant non-asthma medications
- Inability to tolerate or unwillingness to comply with the protocol requirements.
- History of life-threatening asthma
- Any asthma exacerbation within 3 months of the Screening Visit requiring oral or systemic corticosteroids
- History of life-threatening asthma
- Other criteria apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Albuterol Spiromax
Albuterol multi-dose dry powder inhaler (Spiromax) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for the 12 week double-blind period.
Participants then continue into the 40 week open-label period in which they take albuterol multi-dose dry powder inhaler (Spiromax) inhalations of 90 mcg /inhalation as required (PRN).
|
Albuterol as a dry-powder inhaled orally using the Spiromax inhaler. Each inhalation delivers 90 micrograms (mcg). During the 12-week double-blind period, participants take two (2) inhalations four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime for a total dose of 720 micrograms per day for those paricipants randomized to the Albuterol treatment arm. The double-blind period is followed by a 40-week open-label period in which all study participants will take Albuterol Spiromax 90 micrograms (mcg)/inhalation as needed (PRN).
Other Names:
|
Placebo Comparator: Placebo Spiromax
Placebo delivered using a multi-dose dry powder inhaler (Spiromax) as 2 inhalations four times a day for the 12 week double-blind period.
Participants then continue into the 40 week open-label period in which they administer albuterol multi-dose dry powder inhaler (Spiromax) inhalations of 90 mcg /inhalation as required (PRN).
|
Albuterol as a dry-powder inhaled orally using the Spiromax inhaler. Each inhalation delivers 90 micrograms (mcg). During the 12-week double-blind period, participants take two (2) inhalations four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime for a total dose of 720 micrograms per day for those paricipants randomized to the Albuterol treatment arm. The double-blind period is followed by a 40-week open-label period in which all study participants will take Albuterol Spiromax 90 micrograms (mcg)/inhalation as needed (PRN).
Other Names:
Placebo as a dry-powder inhaled orally using the Spiromax inhaler.
During the 12-week double-blind period, participants take two (2) inhalations four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Participants With Treatment-Emergent Adverse Events
Time Frame: Day 1 to Day 49 (study termination)
|
Adverse events (AEs) summarized in this table are those that began or worsened after treatment with study drug (treatment-emergent AEs).
An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug.
Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities.
Relation of AE to treatment was determined by the investigator.
Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.
|
Day 1 to Day 49 (study termination)
|
Changes From Screening in the Results of the Physical Examination That Are Clinically Significant in the Opinion of the Investigator
Time Frame: Days -15 to -8 (Screening), Week 12, Week 52
|
A complete physical examination was planned at study screening, week 12 and week 52 or early termination/discontinuation of the participant.
At weeks 12 and 52,the qualified healthcare professional was to evaluate whether each physical finding is a new finding, worsening, improvement or resolution of an existing condition compared with the baseline physical exam.
Where possible, the same qualified healthcare professional that performed the physical examination at study screening should perform all the scheduled physical examinations.
|
Days -15 to -8 (Screening), Week 12, Week 52
|
Changes From Screening in the Results of the Laboratory Evaluations That Are Clinically Significant in the Opinion of the Investigator
Time Frame: Days -15 to -8 (Screening), Week 12, Week 52
|
Blood samples were to collected for laboratory evaluations at the screening visit and at weeks 12 and 52 or early termination/discontinuation of the participant.
The blood samples were to be drawn after an overnight fast of at least 6 hours and analyzed by a central laboratory.
|
Days -15 to -8 (Screening), Week 12, Week 52
|
Changes From Screening in the Results of the Electrocardiograms (ECGs) That Are Clinically Significant in the Opinion of the Investigator
Time Frame: Days -15 to -8 (Screening), Week 12, Week 52
|
A standard 12-lead ECG was to be performed at screening and at week 12 and week 52 (TV15) or early termination/discontinuation of the participant.
The ECG recording methods were to be centralized and standardized across all study subjects.
|
Days -15 to -8 (Screening), Week 12, Week 52
|
Changes From Screening in the Vital Signs That Are Clinically Significant in the Opinion of the Investigator
Time Frame: Days -15 to -8 (Screening), Week 12, Week 52
|
Vital sign measurements (heart rate and blood pressure) were to be evaluated as part of the safety profile assessment.
The participant was to be seated at least 2 minutes before vital signs were performed.
Either an electronic or manual sphygmomanometer could be used.
|
Days -15 to -8 (Screening), Week 12, Week 52
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Hypersensitivity, Immediate
- Bronchial Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity
- Asthma
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Adrenergic Agonists
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Reproductive Control Agents
- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta-Agonists
- Tocolytic Agents
- Albuterol
Other Study ID Numbers
- ABS-AS-306
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
Clinical Trials on Albuterol Spiromax
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedExercise-Induced Bronchoconstriction (EIB)United States
-
Teva Branded Pharmaceutical Products R&D, Inc.Completed
-
Teva Branded Pharmaceutical Products R&D, Inc.Completed
-
Teva Branded Pharmaceutical Products R&D, Inc.Completed
-
Teva Branded Pharmaceutical Products R&D, Inc.Completed
-
Fundación Pública Andaluza Progreso y SaludCompleted
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedAsthmaUnited States, Thailand
-
Teva Branded Pharmaceutical Products R&D, Inc.Completed
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedAsthma | Chronic Obstructive Pulmonary Disease (COPD)United States
-
Teva Branded Pharmaceutical Products R&D, Inc.Completed